Trials / Recruiting
RecruitingNCT06861010
Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Tanta University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality. A variety of patient-related and procedure-related factors have been associated with higher rates of PEP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Placebo | Placebo tablets will have the same look and appearance of ondansetron. |
| DRUG | Ondansetron | ondansetron is commonly used as anti-emetics to prevent and treat chemotherapy-induced vomiting and nausea |
Timeline
- Start date
- 2025-03-01
- Primary completion
- 2026-12-20
- Completion
- 2026-12-20
- First posted
- 2025-03-06
- Last updated
- 2026-03-13
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06861010. Inclusion in this directory is not an endorsement.